Stock ALTME TME PHARMA N.V.
Add to a list
To use this feature you must be a member
Log inSign up

News TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Market Closed - Euronext Paris
Other stock markets
 16:35:19 03/05/2024 BST 		5-day change 1st Jan Change
0.2485 EUR +2.05% Intraday chart for TME Pharma N.V. -0.20% +8.04%
04-25 TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
04-23 TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
TME Pharma Publishes 2023 Financial Results and Provides Operating Update
BU
TME PHARMA ANNOUNCES 33% OF PATIENTS RECEIVING NOX-A12 IN COMBINATION WITH BEVACIZUMAB AND RADIOTHERAPY ACHIEVE TWO-YEAR SURVIVAL IN GLORIA PHASE 1/2 TRIAL IN BRAIN CANCER
AQ
TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer
BU
TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer
CI
TME Pharma: Fast Track designation in glioblastoma
CF
TME Pharma N : Inside Information / Other news releases
PU
TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer
BU
TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer
CI
TME Pharma N : receives US FDA Fast Track designation for lead asset NOX-A12 in brain cancer
PU
Invest Securities Keeps TME Pharma at Buy, Trims PT
MT
TME PHARMA : Invest Securities slightly adjusts its target
CF
TME Pharma Provides Results of First Exercise of Warrants Z
BU
TME Pharma: green light from the FDA to launch a ph.II trial
CF
TME Pharma N.V. Announces FDA Clearance of Investigational New Drug Application for Nox-A12 Phase 2 Trial in Brain Cancer
CI
TME PHARMA PROVIDES RESULTS OF FINAL EXERCISE OF WARRANTS Y: ADDITIONAL EUR854K RAISED AND EXTENSION OF CASH RUNWAY FROM MAY INTO JULY 2024
AQ
TME Pharma: end of convertible bond program
CF
TME Pharma Raises EUR1.5 Million to Buy Back Convertible Bonds
MT
TME Pharma N.V. announced that it expects to receive ?1.479999 million in funding
CI
TME PHARMA PROVIDES UPDATE ON NUMBER OF OUTSTANDING SHARES AND WARRANTS FOLLOWING FIRST WARRANT Y EXERCISE PERIOD
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALTME Stock
  4. News TME Pharma N.V.